Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL3786814 | 0.92 | DAO (0.37) | DAODDO | |
| SCHEMBL2748991 | 0.76 | KDM4E (0.33) | DAODDO | |
| SCHEMBL2749439 | 0.75 | KDM4E (0.38) | — | |
| SCHEMBL2749175 | 0.74 | ESR1 (0.39) | DAODDO | |
| SCHEMBL2749195 | 0.72 | IDO1 (0.36) | DAODDO | |
| SCHEMBL3786818 | 0.69 | SLC40A1 (0.31) | DAODDO | |
| SCHEMBL8840867 | 0.69 | — | — | |
| SCHEMBL2749066 | 0.68 | IDO1 (0.33) | — | |
| SCHEMBL2748524 | 0.68 | KDM4E (0.33) | — | |
| SCHEMBL2749359 | 0.68 | KDM4E (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2265270-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | DAO 2784/4885DDO 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.